Abstract
The article presents data on the use of the Arfa Combi diet supplement in patients with type 2 diabetes and dyslipidemia. All patients were divided into 3 groups of 20 people: Group 1 took the Arfa Combi dietary supplement and statins; Group 2 took only Arfa Combi; Group 3 had only statins taken on the basis of hypoglycemic therapy. In the dynamics of treatment, all patients had glycemia fasting, glycemia in 2 hours, and total cholesterol and triglycerides determined. According to the results of the study, it was found that in patients with diabetes type 2, the Arfa Combi dietary supplement had adequate anti-sugar and lipid-lowering properties, and a possible decrease in total cholesterol and triglycerides was observed.
References
1. Анциферов М.Б. Роль таурина и его дефицита в организме человека и животных // Фарматека. — 2012. — Vol. 16. — P. 60-65.
2. Lee J., Son H., Ryu O.H. Management Status of Cardiovascular Disease Risk Factors for Dyslipidemia among Korean Adults // Yonsei medical journal. — 2017. — Vol. 58 (2). — P. 326-338.
3. Chen W., Guo J., Zhang Y., Zhang J. The beneficial effects of taurine in preventing metabolic syndrome // Food & function. — 2016. — Vol. 7 (4). — P. 1849-1863.
4. Hansen S.H., Birkedal H., Wibrand F., Grunnet N. Taurine and regulation of mitochondrial metabolism. In Taurine // Springer, Cham. — 2015. — Vol. 9 — P. 397-405.
5. Pandya K.G., Budhram R., Clark G.J., Lau-Cam C.A. Taurine can enhance the protective actions of metformin against diabetes-induced alterations adversely affecting renal function. In Taurine // Springer, Cham. — 2015. — Vol. 9. — P. 227-250.
6. Sirdah M.M. Protective and therapeutic effectiveness of taurine in diabetes mellitus: A rationale for antioxidant supplementation. Diabetes & Metabolic Syndrome // Clinical Research & Reviews. — 2015. — Vol. 9 (1). — P. 55-64.
7. Анциферов М.Б. Роль таурина и его дефицита в организме человека и животных // Фарматека. — 2012. — № 16. — P. 60-65.
8. Александров А.А. Возможности применения фитопрепарата Арфа® Комби в лечении сахарного диабета и нарушения толерант- ности к глюкозе // Ендокринологія. — 2014. — № 1. — C. 38-43.
9. Pastromas S., Terzi A.B., Tousoulis D., Koulouris S. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus // International journal of cardiology. — 2008. — Vol. 126 (1). — P. 3-12.
2. Lee J., Son H., Ryu O.H. Management Status of Cardiovascular Disease Risk Factors for Dyslipidemia among Korean Adults // Yonsei medical journal. — 2017. — Vol. 58 (2). — P. 326-338.
3. Chen W., Guo J., Zhang Y., Zhang J. The beneficial effects of taurine in preventing metabolic syndrome // Food & function. — 2016. — Vol. 7 (4). — P. 1849-1863.
4. Hansen S.H., Birkedal H., Wibrand F., Grunnet N. Taurine and regulation of mitochondrial metabolism. In Taurine // Springer, Cham. — 2015. — Vol. 9 — P. 397-405.
5. Pandya K.G., Budhram R., Clark G.J., Lau-Cam C.A. Taurine can enhance the protective actions of metformin against diabetes-induced alterations adversely affecting renal function. In Taurine // Springer, Cham. — 2015. — Vol. 9. — P. 227-250.
6. Sirdah M.M. Protective and therapeutic effectiveness of taurine in diabetes mellitus: A rationale for antioxidant supplementation. Diabetes & Metabolic Syndrome // Clinical Research & Reviews. — 2015. — Vol. 9 (1). — P. 55-64.
7. Анциферов М.Б. Роль таурина и его дефицита в организме человека и животных // Фарматека. — 2012. — № 16. — P. 60-65.
8. Александров А.А. Возможности применения фитопрепарата Арфа® Комби в лечении сахарного диабета и нарушения толерант- ности к глюкозе // Ендокринологія. — 2014. — № 1. — C. 38-43.
9. Pastromas S., Terzi A.B., Tousoulis D., Koulouris S. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus // International journal of cardiology. — 2008. — Vol. 126 (1). — P. 3-12.
Downloads
Download data is not yet available.